About Us  |   Contact Us  |   Register  | Login  |   

Follow HedgeWorld on Twitter HedgeWorld on LinkedIn






Alternative Reality

Search the Blog
Alternative Reality Categorys
Commodities ( 4 )
Credit (3)
Daily News  (13)
Foreign exchange/currency  (0)
Form D filings (15)
Hedge fund performance(2)
High-frequency trading(1)
Evil Speculators (0)
Lipper hedge fund performance(0)
Managed Futures (5)
News Roundup (4)
Research (1)
Video (31)


Valeant's sweetener comes off a little defensive
By Reuters Breakingviews
Wednesday, May 28, 2014

Valeant Pharmaceuticals International comes off oddly defensive in its latest advance on Allergan. A sweetened $49 billion bid for the Botox maker disappointed investors in both companies. The use of a messy financial instrument probably didn't help, especially after the target pushed back hard on the deal math and compared its suitor to Tyco. Valeant has more work to do to reclaim the role of aggressor.

The Canadian company channeled Sun Tzu last month, enlisting hedge fund boss Bill Ackman to help spring its unsolicited offer on Allergan. With an estimated premium of about 23 percent, $2.7 billion of projected annual savings from the deal and the impressive track record of its own stock during years of using an acquisitive strategy, Valeant immediately put its quarry on the back foot.

It didn't take long to realize Valeant was keeping a big portion of the synergies for itself, leaving it scope to offer more. Allergan also started punching back. The New Jersey-based company on Tuesday questioned Valeant's accounting, the stability of its management team and the viability of achieving certain R&D savings and tax cuts. In a particularly bold counterattack, Allergan raised the specter of Tyco, the conglomerate whose rollup strategy came undone amid scandal over a decade ago.

Valeant's enhanced offer seems tame by comparison. The stocks of both companies tumbled 3 percent. At about $166 a share, the bid is at least 8 percent short of what a recent JPMorgan survey found Allergan investors want. Valeant did throw in contingent value rights based on potential sales of an eye drug, but such contracts are often tricky to structure and value. It also suggests that Valeant, which would be indebted at more than eight times EBITDA after buying Allergan, may be running out of firepower.

Its 176-page retort included "personal reflections" from managers attempting to present Valeant as something more than just a ruthless M&A machine. It also redoubled efforts to illustrate its cost-cutting capabilities and explain its growth, while invoking other acquirers like Novartis in a rebuttal of the Tyco dig. It all sounds like a company trying to combat the possibility that its business model of needing ever-larger deals is perceived to be on shaky ground. Valeant probably needs to reshape its message and its bid yet again to come out on top.

Jeffrey Goldfarb

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.



Copyright © 1999-2014 Reuters HedgeWorld All rights reserved.






Lipper    Privacy   User Policy  Legal Disclosure Copyright/DMCA  Site Map    FAQ    Glossary  Thomson Reuters for Hedge Funds
All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of HedgeWorld content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. HedgeWorld is a registered trademark of Thomson Reuters.